Key result
Carvedilol linked to ~28% lower all-cause mortality vs Nebivolol in STEMI patients.
Why the study?
Nebivolol and Carvedilol have distinct pharmacological properties, but their comparative long-term outcomes in STEMI patients with preserved LVEF treated with DES were unclear.
Does nebivolol compared to carvedilol reduce all-cause death and MACE in STEMI patients with preserved LVEF treated with drug-eluting stents?
Cohort (n=6,711)
Yes
Does nebivolol compared to carvedilol reduce all-cause death and MACE in STEMI patients with preserved LVEF treated with drug-eluting stents?
Hazard Ratio: 1.391 (95% CI 1.04–1.86)
Absolute Event Rate: 3.3% vs 2.4%
p-value: p=0.027
In STEMI patients with preserved LVEF treated with drug-eluting stents, discharge prescription of carvedilol is associated with significantly lower long-term mortality and MACE compared to nebivolol.
No takes yet. Share an insight, caveat, or question.
May favor carvedilol over nebivolol at STEMI discharge; hypothesis-generating and should not yet alter practice pending RCTs.
Susanti et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) with preserved LVEF (n=6,711). Nebivolol vs. Carvedilol was evaluated on All-cause death (HR 1.391, 95% CI 1.040-1.860, p=0.027). Nebivolol prescription at discharge was associated with a higher 3-year risk of all-cause death compared to Carvedilol (3.3% vs 2.4%; HR 1.391, 95% CI 1.040-1.860; P=0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: